HCM · HUTCHMED (China) Limited
$14.36
+0.56% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$1B
Trailing P/E
143.6
Forward P/E
55.4
Dividend yield
0.0%
Beta
0.36
Avg volume
0M
Employees
2K
Daily Change %
0.56%
5 Days Change
1.64%
10 Days Change
5.78%
30 Days Change
-0.63%
60 Days Change
17.24%
Month to Day Change
-1.99%
Year to Day Change
7.13%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HCM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
Goldman Sachs
Neutral$14.00
-2.5% vs priceBank of America
Buy$17.00
+18.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Goldman Sachs | Maintains | Neutral | $16.00 → $14.00 |
| 2026-07-07 | Bank of America | Maintains | Buy | $20.00 → $17.00 |
| 2026-03-10 | Bank of America | Maintains | Buy | $21.00 → $20.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 6.1% above the 50-day MA ($13.54).
- bullish: Price vs 200-day MA: Trading 8.3% above the 200-day MA ($13.26).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.01) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($9.99) and high ($16.05).
HCM Price Chart
Loading chart for HCM…
Fundamentals
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
RDY
Dr. Reddy's Laboratories Ltd
$11B -5.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.